Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider. 

  • Ξεκινήστε βυθίζοντας την πιπέτα μέσα στο υγρό που σκοπεύετε να αναρροφήσετε [undo]
  • Osmosis [undo]
  • Εκπαιδεύοντας τον ασθενή σας στην αυτοδιαχείριση [undo]
  • DNA Amplification [undo]
  • Відмовитися від ліків, оскільки я вже почуваюся краще. [undo]
  • Insulin detemir [undo]
  • Activates vasopressin receptors [undo]
  • Option 2: Only B is correct [undo]
  • Option 3 [undo]
  • Diffusion [undo]
  • Залиште лікарню та обсудіть це питання ще з кимось. [undo]
  • Option 2 [undo]
  • Secvențierea genomului [undo]
  • Diploid și haploid [undo]
  • Trăsături [undo]
  • Omnom! [undo]
  • Facem cunoștință cu laboratorul și cu ceilalți studenți [undo]
  • Definiția 1 [undo]
  • Preparation of liquid cultures [undo]
  • Permanently stop taking metformin [undo]
  • Getting worse [undo]
  • Decision Point [undo]
  • Sitagliptin [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21125
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway